Sales Growth YoY (Last Twelve Months): 89bio Pharma (ETNB)

Graphic logo of 89bio, Inc. (ETNB)

The high margin potential of 89bio, Inc. (ETNB) is based on the unique drug Pegozafermin and a patented FGF21 modification method. Year-over-year product sales dynamics for the TTM clearly illustrate this growth, where the value of 0.00 captures the metric level. Business development relies on partnerships with medical centers in liver therapy and complete independence from geopolitical risks within the protected humanitarian sector.

Sales Growth YoY (Last Twelve Months): 89bio Corp (ETNB) for 02/11/2024 - 02/20/2024

Analytical breakdowns for 89bio, Inc.

- market value and analyst target forecast:
- company stock exchange capitalization indicators:
Summary company analytics:89bio Corp (ETNB)
Mass-produced product of 89bio

For the biotechnology sector company 89bio, Inc. (ETNB), the commercialization of pegozafermin in the MASH market serves as the key value driver. This metric measures the relative change in rolling annual revenue compared to the same interval in the previous period, revealing the actual pace of business scaling. The 12-month annual revenue change trajectory on GURU.Markets visualizes this vector, separating random fluctuations from sustainable growth. Positive momentum will confirm the future potential for free cash flow.

Who 89bio, Inc. competes with

Ascendis (ASND) - Trailing Twelve Months Revenue Growth|MDGL - Sales Growth YoY (Last Twelve Months)|CORT: Sales Growth YoY (Last Twelve Months)|RYTM: Sales Growth YoY (TTM)|AKRO - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Metsera Therapeutics|MoonLake Corp (MLTX) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) crinetics.com (CRNX)|Revenue Growth YoY (Last 12 Months) newamsterdampharma.com NAMS|Sales Growth YoY (Last Twelve Months) Soleno Therapeutics Inc SLNO|Sales Growth YoY (TTM) Amicus Therapeutics Inc FOLD|Agios - Sales Growth YoY (TTM)|Structure Corp - Revenue Change YoY (Last 12 Months)|mimedx.com (MDXG) - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Sales Growth YoY (TTM)|Sales Growth YoY (Last Twelve Months) MBX|Sales Growth YoY (Last Twelve Months) Altimmune Pharma (ALT)|Sales Growth YoY (Last Twelve Months) AARD (Aardvark Therapeutics Corp)|Sales Growth YoY (TTM) SGMT (Sagimet Biosciences, Inc.)|BioAge (BIOA) - Trailing Twelve Months Revenue Growth|BMEA: Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) QNCX (Quince Therapeutics Inc)|GUTS (Fractyl) - Revenue Growth YoY (Last 12 Months)|vTv Therapeutics, Inc. - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Agape ATP Corp.|Revenue Growth YoY (Last 12 Months) Pluri (PLUR)|Sales Growth YoY (TTM) SYBX|Annual Revenue Growth (Last Twelve Months) Lipocine Inc|Sales Growth YoY (Last Twelve Months) Matinas BioPharma Holdings MTNB|Annual Revenue Growth (Last Twelve Months) Spruce Biosciences (SPRB)|GLTO: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Sales Growth CTCX|LUMO (Lumos Pharma) - Revenue Growth YoY (Last 12 Months)|Sales Growth YoY (Last 12 Months) ONVO|RDUS (Radius Pharmaceuticals) - Sales Growth YoY (TTM)